3//SEC Filing
Vivo Capital VIII, LLC 3
Accession 0001567619-21-002191
CIK 0001831363other
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 5:05 PM ET
Size
13.1 KB
Accession
0001567619-21-002191
Insider Transaction Report
Form 3
Vivo Capital VIII, LLC
10% Owner
Holdings
- (indirect: Vivo Capital Fund VIII, L.P.)
Series B Preferred Stock
→ Common Stock (1,569,047 underlying) - (indirect: Vivo Capital Surplus Fund VIII, L.P.)
Series B Preferred Stock
→ Common Stock (216,666 underlying) - (indirect: Vivo Capital Fund VIII, L.P.)
Series C Preferred Stock
→ Common Stock (364,138 underlying) - (indirect: Vivo Capital Surplus Fund VIII, L.P.)
Series C Preferred Stock
→ Common Stock (50,282 underlying)
Footnotes (4)
- [F1]Each share of Series B Preferred Stock will automatically convert on a 1-for-2.2 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. Such conversion is reflected in the amount of common stock underlying the security.
- [F2]Reflects a 1-for-14 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
- [F3]Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of each of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., the record holder of the securities. Dr. Hongbo Lu is a Managing Partner at Vivo Capital LLC and a member of the Issuer's board of directors. Frank Kung, Edgar Engleman and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- [F4]Each share of Series C Preferred Stock will automatically convert on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
Documents
Issuer
Terns Pharmaceuticals, Inc.
CIK 0001831363
Entity typeother
Related Parties
1- filerCIK 0001618789
Filing Metadata
- Form type
- 3
- Filed
- Feb 3, 7:00 PM ET
- Accepted
- Feb 4, 5:05 PM ET
- Size
- 13.1 KB